What is MKGAF stock price today?

MKGAF (MERCK Kommanditgesellschaft auf Aktien) stock is trading at $138.51 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is MKGAF stock going up or down today?

MKGAF stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy MKGAF stock now?

The decision to buy MKGAF depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is MKGAF a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for MKGAF based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is MKGAF stock overvalued or undervalued?

MKGAF currently trades at a P/E ratio of 19.56 relative to earnings. Our DCF calculator provides intrinsic value estimates to help determine if MKGAF is fairly priced.

What is MKGAF's P/E ratio?

MKGAF has a price-to-earnings (P/E) ratio of 19.56, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is MKGAF's market cap?

MKGAF (MERCK Kommanditgesellschaft auf Aktien) has a market capitalization of $60.22 billion, making it a mid-cap stock.

What is MKGAF's price to book ratio?

MKGAF trades at a price-to-book (P/B) ratio of 1.78, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does MKGAF pay dividends?

Yes, MKGAF pays dividends with a current yield of 0.02%. Dividend payments provide income for investors in addition to potential stock price appreciation.

What is MKGAF's dividend yield?

MKGAF's dividend yield is 0.02%, calculated as annual dividends divided by the current stock price. This represents the annual return from dividends alone.

Is MKGAF stock a good long-term investment?

MKGAF's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is MKGAF's revenue growth rate?

MKGAF has shown revenue growth of -0.0% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, MKGAF is profitable with a profit margin of 0.1%. This indicates the company generates 0.1 cents of profit for every dollar of revenue.

What are the risks of investing in MKGAF?

Key risks for MKGAF include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does MKGAF compare to its competitors?

Compare MKGAF to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize MKGAF's performance and positioning.

What is MKGAF's stock price target for 2026?

Our AI model provides price targets for MKGAF based on fundamental analysis: Bull case $180.06 (+30%), Base case $159.29 (+15%), Bear case $124.66 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about MKGAF?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for MKGAF. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is MKGAF's next earnings report?

MKGAF reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

MKGAF - MERCK Kommanditgesellschaft auf Aktien

NYSE * Healthcare * Drug Manufacturers - Specialty & Generic

$138.51

+$0.59 (+0.43%)

About MERCK Kommanditgesellschaft auf Aktien

Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.

MKGAF Key Statistics

Market Cap

$60.22B

P/E Ratio

19.56

P/B Ratio

1.78

EPS

$7.08

Dividend Yield

0.02%

Revenue Growth

-0.0%

Profit Margin

0.1%

Employees

59,077

How MKGAF Compares to Peers

MKGAF ranks 2nd most undervalued by P/E ratio among peers

MKGAF is the smallest among peers, which may offer higher growth potential

P/E Rank

of 6

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
MKGAF(This stock)	$60.22B	19.6	-0%	0.1%	-
LLYEli Lilly	$823.33B	40.2	0%	0.3%	vs LLY
JNJJohnson &	$564.35B	21.2	0%	0.2%	vs JNJ
PFEPfizer Inc	$156.77B	20.3	-0%	0.1%	vs PFE
MRKMerck &	$294.39B	16.4	0%	0.3%	vs MRK
ABBVAbbvie Inc	$368.57B	87.6	0%	0.1%	vs ABBV

MERCK Kommanditgesellschaft auf Aktien Company Information

Headquarters: Frankfurter Strasse 250, Darmstadt, Germany, 64293, undefined
Website: www.emdgroup.com
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

About MERCK Kommanditgesellschaft auf Aktien

MKGAF Key Statistics

How MKGAF Compares to Peers

MERCK Kommanditgesellschaft auf Aktien Company Information

Upcoming Events for MKGAF